Well my debate with my new BF ( best friend ) who is obviously an AI
My comments within (..)
But won't the LDO's ( Davita nd Fresenius ) make more $ dispensing cheap generics by keeping the difference between the CMS WAC and what they can negotiate with the generic manufacturers..... ( I asked )
That is a highly perceptive point, ( boy my AI thinks I'm so smart ) ... but the mechanics of Medicare’s TDAPA reimbursement rules prevent large dialysis organizations (LDOs) from keeping a spread on generic medications during the transitional phase.
While capturing the "spread" (the difference between a high government benchmark and a deeply discounted wholesale price) is a classic pharmaceutical strategy, CMS explicitly designed the Transitional Drug Add-on Payment Adjustment (TDAPA) to block this exact behavior.
Here is exactly why LDOs cannot profit from dispensing cheap generics, and how that alters the math for a brand like Oxylanthanum Carbonate (OLC):
( Ah Ha )
1. TDAPA Pays on Actual Market Prices, Not List PricesMedicare does not reimburse drugs under TDAPA based on a static list price like Wholesale Acquisition Cost (WAC).
Instead, it uses Average Sales Price (ASP).
The ASP Calculation: ASP is calculated retroactively by CMS based on the actual net revenue manufacturers receive, inclusive of all volume discounts, rebates, and price concessions given to buyers like DaVita or Fresenius.
The Dynamic Squeeze:
If an LDO uses its massive scale to negotiate a generic binder down to pennies per pill, the manufacturer is legally required to report those deeply discounted transactions to CMS.
Within two quarters, CMS drops the official ASP for that generic to mirror those exact discounts.
Zero Spread:
Because Medicare pays exactly 100% of that dynamically shrinking ASP, the reimbursement drops right alongside the purchase price.
The LDO gets paid exactly what they spent; there is no margin to pocket.
2. The Universal Flat Fee Appears Independent of Drug ChoiceTo offset the operational costs of handling thousands of pills, CMS pays a flat monthly add-on fee of $36.41 per patient claim. This fee is a fixed administrative payment. Crucially, a facility receives this same $36.41 per month regardless of whether they dispense 300 cheap generic sevelamer pills or 90 premium OLC tablets.
Because the administrative fee is constant, it does not incentivize choosing a generic over a brand.
3. High Product Margin vs. Total Care Value
Because there is zero arbitrage profit on cheap generics under TDAPA, LDOs shift their focus from drug-margin profit to clinical efficiency and penalty avoidance.. ( well we hope so )
When OLC hits the market in 2027, LDOs will look at the total financial equation:
Generic Binder (e.g., Sevelamer) Brand-Name OLC
-------------------------------- -----------------------------
Reimbursement: 100% of Low ASP Reimbursement: 100% of High ASP
Pill Burden: 10-12 massive pills/day Pill Burden: 3 small pills/day
Adherence: Low Adherence: High
Hyperphosphatemia Risk: High Hyperphosphatemia Risk: Low
Result: Risks Quality Score Penalties Result: Protects Quality Score Revenue
If a patient skips their massive generic pills, their serum phosphorus spikes.
This directly triggers penalties under the CMS ESRD Quality Incentive Program (QIP).
Since Medicare is picking up the entire bill for OLC via TDAPA anyway, the LDO’s most logical financial play is to prescribe the high-adherence brand to protect their global dialysis revenue, rather than trying to manage a non-compliant patient on a generic that yields zero spread.
The Catch:
What Happens in 2029?
Your strategy of "dispensing cheap generics to maximize profits" will become entirely true starting in 2029.
Once OLC's two-year TDAPA window closes and its costs are permanently rolled into the single, flat per-treatment base rate (Phase 2), Medicare will stop paying 100% ASP for it.
At that exact moment, every dollar spent on premium OLC eats into the clinic's fixed profit margin.
In 2029, the LDOs will aggressively pivot back to cheap generics to keep the difference—unless the manufacturer of OLC slashes its commercial price to match generic cost levels.
( or unless Kidney Patient Care changes get approved in Congress and TDAPA goes from 2 to 3 yrs and then a gradual taper after that .)
My comment within (...) plus I added the bold highlights
Kiwi
Market Data 
Markets 
